The main outcomes of the study stratified according to device type
| 5-Year cumulative incidence and 95% CI | ICD only versus CRT–ICD, log-rank p | |||
| Entire cohort (n=334) | ICD only (n=298) | CRT–ICD (n=36)* | ||
| CVS mortality end point | 8% (4 to 12) | 6% (2 to 10) | 21% (5 to 37) | <0.0001 |
| Appropriate shocks | 13% (7 to 19) | 10% (6 to 14) | 34% (12 to 56) | 0.002 |
| Inappropriate shocks | 21% (15 to 27) | 21% (15 to 27) | 22% (6 to 38) | 0.632 |
| Implant complications | 21% (15 to 27) | 19% (13 to 25) | 36% (18 to 54) | 0.002 |
| Adverse ICD events | 34% (28 to 40) | 34% (28 to 40) | 39% (21 to 57) | 0.113 |
↵* CRT–ICD recipients had a lower FS and had more symptoms than did the rest of the cohort (FS, fractional shortening: 30% vs 39%, respectively (p<0.0001); NYHA, New York Heart Association III/IV: 29% vs 7%, respectively (p=0.003)).
ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronisation therapy; CVS, cardiovascular.